DRR168602
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.350
- OXIDATIVE_PHOSPHORYLATION+0.340
- WNT_BETA_CATENIN_SIGNALING+0.290
- UV_RESPONSE_UP+0.280
- ANGIOGENESIS+0.260
- MYOGENESIS+0.240
- ADIPOGENESIS+0.220
- FATTY_ACID_METABOLISM+0.220
- MYC_TARGETS_V2+0.210
- DNA_REPAIR+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.450
- INTERFERON_GAMMA_RESPONSE-0.400
- ALLOGRAFT_REJECTION-0.350
- IL6_JAK_STAT3_SIGNALING-0.230
- INFLAMMATORY_RESPONSE-0.210
- PROTEIN_SECRETION-0.210
- IL2_STAT5_SIGNALING-0.200
- ANDROGEN_RESPONSE-0.180
- KRAS_SIGNALING_UP-0.170
- TGF_BETA_SIGNALING-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_K3ER45RV | Med | Medulloblastoma | 0.806 |
| 2 | 689c3b5e-8bff-45d0-8165-b4b0e6dbf910 | — | — | 0.801 |
| 3 | TCGA-UF-A71A-01A-22R-A34R-07 | — | — | 0.798 |
| 4 | SRR12475125 | — | — | 0.783 |
| 5 | SJEPD037_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.775 |
| 6 | BS_WRQHPSXQ | Ganglioglioma | — | 0.774 |
| 7 | MNG581 | — | — | 0.767 |
| 8 | SRR11296875 | — | — | 0.762 |
| 9 | SRR2669446 | — | — | 0.757 |
| 10 | R108 | — | — | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.280 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |